Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 2110-2115

  Nisman, Benjamin ^a   Kadouri, Luna ^a   Allweis, Tanir ^b   Maly, Bella ^a   Hamburger, Tamar ^a   Gronowitz, Simon ^c   Peretz, Tamar ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Dep of Orthopaedic Surgery   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER RISK; CELL DIVISION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SYNTHESIS; FEMALE; FOLLOW UP; GENE MUTATION; HAPLOINSUFFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL GROWTH PROCESSES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HAPLOINSUFFICIENCY; HUMANS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; WOMEN'S HEALTH;

EID: 84887292096     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0193     Document Type: Article

References (20)

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
2. Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 2009;69:1273-8.
3. Martins FC, De S, Almendro V, Gonen M, Park SY, Blum JL, et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov 2012;2:503-11.
4. Nisman B, Allweis T, Kadouri L, Mali B, Hamburger T, Baras M, et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med 2013;51:439-47.
5. Gronowitz S, inventor; Ronnerbol Holding AB, assignee. A method and kit for determination of thymidine kinase and use thereof. European patent: WO/2006/091158 A1. 2006 Feb 24.
6. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8.
7. Wintersberger E. Regulation and biological function of thymidine kinase. Biochem Soc Trans 1997;25:303-8.
8. Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1- mediated pathway. Mol Cell Biol 2004;24:514-26.
9. Burga LN, Hu H, Juvekar A, Tung NM, Troyan SL, Hofstatter EW, et al. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression inmammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res 2011;13:R30.
10. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, Altevogt P. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 2008;103:1783-97.
11. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 2008;314:2907-18.
12. Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A 1984;81:7308-12.
13. Ilekis JV, Stark BC, Scoccia B. Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol Reprod Dev 1995;41:149-56.
14. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101:80-7.
15. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336: 1401-8.
16. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev 2001;10:1175-85.
17. Gronowitz JS, Kallander FR, Diderholm H, Hagberg H, Pettersson U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5-12.
18. Li Z, WangY, MaJ, HeJ, Zhou J, He E, et al. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Anticancer Res 2010;30:1295-9.
19. Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 2003;57:447-51.
20. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.